DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION BIOLOGICAL PRODUCT DEVIATION REPORT |
FDA USE ONLY |
||||||||||||||||
Date Received: |
|||||||||||||||||
|
|||||||||||||||||
Date Reviewed: |
|||||||||||||||||
|
|||||||||||||||||
BPD ID: |
|||||||||||||||||
|
|||||||||||||||||
BPD No. |
|||||||||||||||||
* Indicates required information |
|
||||||||||||||||
A. FACILITY INFORMATION |
B. BIOLOGICAL PRODUCT DEVIATION (BPD) INFORMATION |
||||||||||||||||
1. Reporting Establishment Information |
1. Establishment Tracking # |
||||||||||||||||
|
|||||||||||||||||
* Reporting Establishment Name |
2. Date BPD Occurred |
||||||||||||||||
|
|
||||||||||||||||
* Street Address Line 1 |
3. * Date BPD Discovered |
||||||||||||||||
|
|
||||||||||||||||
Street Address Line 2 |
4. * Date BPD Reported |
||||||||||||||||
|
|
||||||||||||||||
* City |
* State |
5. * Description of BPD (use Page 2 for additional space) |
|||||||||||||||
|
|
|
|||||||||||||||
Country |
*Zip Code |
||||||||||||||||
|
|
||||||||||||||||
* Point of Contact |
|||||||||||||||||
|
|||||||||||||||||
* Telephone # |
6. * Description of Contributing Factors or Root Cause |
||||||||||||||||
( ) |
(use Page 3 for additional space) |
||||||||||||||||
|
|||||||||||||||||
|
|||||||||||||||||
2. *Reporting Establishment Identification Number |
|||||||||||||||||
FDA Registration # |
|||||||||||||||||
|
|||||||||||||||||
CLIA # |
|||||||||||||||||
|
7. * Follow-Up (use Page 4 for additional space) |
||||||||||||||||
|
|||||||||||||||||
3.
If the BPD occurred somewhere other than the above |
|||||||||||||||||
* Establishment Name |
|||||||||||||||||
|
|||||||||||||||||
Street Address Line 1 |
8. * Please Enter the 6 Character BPD Code |
||||||||||||||||
|
|
||||||||||||||||
.Street Address Line 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
* City |
* State |
|
|||||||||||||||
|
|
C. UNIT / PRODUCT INFORMATION |
|||||||||||||||
* Country |
* Zip Code |
Please check the type Blood (Continued on Page 5) of product: Non-Blood (Continued on Page 6) |
|||||||||||||||
|
|
||||||||||||||||
4. Establishment Identification Number: |
|||||||||||||||||
FDA Registration # |
|||||||||||||||||
|
|||||||||||||||||
CLIA # |
|||||||||||||||||
|
Biological Product Deviation Report |
B5. DESCRIPTION OF BPD (continued) |
|
Biological Product Deviation Report |
B6. DESCRIPTION OF CONTRIBUTING FACTORS OR ROOT CAUSE (continued) |
|
Biological Product Deviation Report |
B7. FOLLOW-UP (continued) |
|
Biological Product Deviation Report |
|||||||
C1. BLOOD PRODUCTS / COMPONENTS |
|||||||
TOTAL NUMBER OF LOTS: |
|
|
|||||
|
|
|
|||||
Unit # |
Collection Date (MM/DD/YYYY) |
Expiration Date (MM/DD/YYYY) |
Product Code |
Disposition |
Notification (Y,N,RN**) |
||
1.)
|
|
|
|
|
|
||
2.)
|
|
|
|
|
|
||
3.)
|
|
|
|
|
|
||
4.)
|
|
|
|
|
|
||
5.)
|
|
|
|
|
|
||
6.)
|
|
|
|
|
|
||
7.)
|
|
|
|
|
|
||
8.)
|
|
|
|
|
|
||
10.)
|
|
|
|
|
|
||
11.)
|
|
|
|
|
|
||
12.)
|
|
|
|
|
|
||
13.)
|
|
|
|
|
|
||
14.)
|
|
|
|
|
|
||
15.)
|
|
|
|
|
|
||
16.)
|
|
|
|
|
|
||
17.)
|
|
|
|
|
|
||
18.)
|
|
|
|
|
|
Biological Product Deviation Report |
|||||||
C2. NON-BLOOD PRODUCTS |
|||||||
TOTAL NUMBER OF LOTS: |
|
|
|||||
|
|
|
|||||
Lot # |
Expiration Date (MM/DD/YYYY) |
Product Type |
Product Code |
Disposition |
Notification (Y, N) |
||
1.)
|
|
|
|
|
|
||
2.)
|
|
|
|
|
|
||
3.)
|
|
|
|
|
|
||
4.)
|
|
|
|
|
|
||
5.)
|
|
|
|
|
|
||
6.)
|
|
|
|
|
|
||
7.)
|
|
|
|
|
|
||
8.)
|
|
|
|
|
|
||
10.)
|
|
|
|
|
|
||
11.)
|
|
|
|
|
|
||
12.)
|
|
|
|
|
|
||
13.)
|
|
|
|
|
|
||
14.)
|
|
|
|
|
|
||
15.)
|
|
|
|
|
|
||
16.)
|
|
|
|
|
|
||
17.)
|
|
|
|
|
|
||
18.)
|
|
|
|
|
|
Biological Product Deviation Report |
D. ADDITIONAL COMMENTS |
|
Public reporting burden for this collection of information is estimated to average 2 hours per response, including the time for reviewing instructions, searching existing data sources, adhering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Center for Biologics Evaluation and Research
Office of Compliance and Biologics Quality
1401 Rockville Pike, Suite 200N, HFM-600
Rockville, MD 20852-1148
An agency may not initiate a collection activity without first obtaining OMB approval. The approved collection instrument should display a current and valid OMB control number, expiration date, public protection provision, and a burden statement on the approved collection instrument.
FORM
FDA 3486 (7/04) Page
File Type | application/msword |
Author | Brian Perry |
Last Modified By | Jonna Capezzuto |
File Modified | 2007-02-05 |
File Created | 2007-02-05 |